Phathom Pharmaceuticals, Inc. (PHAT) Balance Sheet

The balance sheet has moved from a deficit that widened through 2025 to a more modest position by 2026Q3, but the reported equity figure remains deeply negative. The trajectory suggests that accumulated losses of roughly $1.5B continue to dominate the capital structure, and the improvement appears driven more by reduced debt than by earnings retention. Investors should monitor whether operating breakeven proves durable enough to reverse the deficit over time.

The sharp drop and subsequent rebound in debt suggest a discrete restructuring rather than gradual paydown, and the reported figures do not disclose the terms behind the change. The renewed $168.0M balance in 2026Q3 implies that leverage remains a material feature of the capital structure. Refinancing terms and maturity profile warrant further investigation, since the reported data cannot confirm the cost or timing of obligations.

A current ratio near 1.8 remains serviceable, but the downward path from above 3.5 reflects either rising short-term obligations or a smaller current asset base relative to liabilities. Cash of $184.6M provides a buffer against the modest operating outflows seen in prior quarters. Whether this cushion is sufficient depends on the pace of commercial scaling and the durability of the recent positive operating cash flow.

The near-absence of PP&E and goodwill is consistent with a commercial-stage pharmaceutical company that outsources manufacturing and avoids acquisition-driven intangibles. This lowers impairment risk but also means the asset base offers little hard collateral. Investors should evaluate the composition of the remaining $345.0M in assets to understand how much is realizable.